Immunotherapy IRC @fredhutch

CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model ashpublications.org/blood/article/… 1/2014/533073/CD45-Directed-Radioimmunotherapy-with-the-Alpha . @fredhutch

Researchers optimized a method to isolate nuclei from flash‑frozen mouse colon tissue for single‑nuclei RNA sequencing using  Miltennyi’s lysis buffer and Octo-dissociator with chillers. The protocol improved nuclei RNA quality and counting prior to fixing nuclei for the 10x. FLEX- Multiplex protocol, supporting high‑quality, cost-effective molecular profiling when other single‑cell methods aren’t possible. @HutchInnovation bit.ly/4ueaNZi

Autoantibodies cause autoimmune disease, shape infection outcomes, and alter cancer immunotherapy. But what role might they play in neuropsychiatric disease? In our new preprint, Katlyn Nemani and @JillianRJaycox take on this question in schizophrenia. 🧵 biorxiv.org/content/10.648…

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…

pubmed.ncbi.nlm.nih.gov/41986623/ In 4,258 patients, donor age affected outcomes differently depending on donor type. @fredhutch researchers & collaborators found while younger family donors showed rising risk once donors were ~38, matched unrelated donors stayed low‑risk until ~50 with better overall survival, allowing for more personalized donor choices.

fredhutch.org/content/www/en… via @fredhutch

CAR‑T saves lives but can disrupt humoral immunity. New data show CD19/20 CAR‑T recipients often lack protective antibodies to ~1/3 of vaccine‑preventable pathogens for up to a year, with even larger gaps after BCMA CAR‑T. Re‑vaccination helps—especially in patients with higher B‑cell counts. @fredhutch Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response | Nature Communications

PhD (or equivalent) students within 2 years of graduation or who have graduated in the last year - Apply to visit with faculty at @FredHutch and hear about opportunities at this world-renowned institution. Food, lodging and travel covered! Apply by June 1: fredhutch.org/en/research/in…

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries | New England Journal of Medicine nejm.org/doi/10.1056/NE…

Tyrosine kinase inhibitor drugs can be highly effective against chronic myeloid leukemia, but access to these life-saving drugs and necessary clinical support is limited in low- and middle-income countries. The authors report that these barriers can be overcome to enable long-lasting remissions in resource-limited settings. @fredhutch @JerryRadich Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries | New England Journal of Medicine

Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.  @Fredhutch Matthias Stephan Lab discovery: new mRNA-based foam coats the esophagus, delivering apoptosis-inducing therapy directly to tumors. In vitro, it showed 110× higher tumor regression than suspension and boosted radiotherapy effects—offering hope for home-based, less disruptive treatment. Matthias Stephan to present findings at Digestive Disease Week: ddw.org/?doing_wp_cron…

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation ashpublications.org/blood/article/…

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission." bit.ly/4rccFA0 Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission. bit.ly/4rccFA0 Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

"Huge thanks to an amazing team, mentors, and collaborators at @fredhutch @FH_IRC and globally 📄 Nature: “The ubiquitin ligase KLHL6 drives resistance to CD8⁺ T cell dysfunction” 🔗 (nature.com/articles/s4158…)

@HutchInnovation @fredhutch Evaluating the practical aspects and performance of commercial single-cell RNA sequencing technologies academic.oup.com/nargab/article…